Sachs Associates’ Post

💓 Magenta Medical Ltd. developed the left ventricular assist device system, which is the world’s smallest heart pump, indicated for use in high-risk coronary operations or for unstable cardiogenic shock patients. The new funding will be used to support US clinical programmes in multiple mechanical circulatory indications. 💬 Magenta Medical's CEO, Dr. David Israeli, MD, said, "Magenta is thrilled to add these exceptional MedTech investors to its mission of disrupting the MCS space. 👉 Learn more: https://lnkd.in/dKgzJJKt 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dfUtcJtG #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions

What will the Medtech industry look like on a global scale in 2024? Today, we'd like to share McKinsey's article "What to expect from Medtech in 2024". While primarily focusing on the USA, the authors also address international chances and challenges. ➡️ https://lnkd.in/epQMG7F7   What are your predictions for this year? We'd love to hear from you in the comments! #bgs #bgsbetagammaservice #irradiation #medicaldevices #medtech

EOS Intelligence's new Perspective: Eyeing the potential of the emerging Pulsed Field Ablation market, MedTech giants such as Johnson & Johnson MedTech, Medtronic, and Boston Scientific entered the stage with their newly developed PFA devices. Being early entrants, they have the potential to expand their market shares in the cardiac ablation market by grabbing shares from thermal ablation procedures. #pfa #pulsedablation #thermalablation #atrialfibrillation #perspectives #eosperspectives #eosintelligence https://lnkd.in/dvZGnV79

The growing adoption of Pulsed Filed Ablation indicates that it has the potential to become the preferred method for treating Atrial Fibrillation (AFib) over the existing treatments, such as thermal catheter ablation and surgical ablation procedures. Please find EOS Intelligence's this week's perspective on this emerging technology #pfa #atrialfibrillation #thermalablation

𝐌𝐑𝐈 𝐂𝐨𝐧𝐭𝐫𝐚𝐬𝐭 𝐌𝐞𝐝𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/dysXKfGv The global MRI contrast media market, valued at USD 1.45 billion in 2023, is projected to reach USD 1.97 billion by 2034, growing at a CAGR of 5.20%. This market has evolved significantly due to technological advancements, the increasing prevalence of chronic diseases, and a rising demand for precise diagnostic tools. MRI contrast media, crucial for enhancing tissue visibility during imaging, are provided by major players like Bayer, Bracco, GE Healthcare, and Guerbet. These companies focus on research and development, strategic collaborations, and innovation to meet healthcare needs. Advances in MRI technology and a higher incidence of conditions such as cardiovascular diseases and cancers drive the demand for contrast agents, enhancing diagnostic accuracy and early detection. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞: Paramagnetic and Superparamagnetic. ▶𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧: Intravenous, Oral, and Others. ▶𝐄𝐧𝐝-𝐔𝐬𝐞𝐫: Standalone Imaging Centers and Hospitals. ▶𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐲: North America, Europe, APAC, Latin America, and Middle East & Africa. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝:          GE HealthCare, Siemens Healthineers, Philips, Bracco, Bayer HealthCare Diabetes Care, Guerbet, FUJIFILM Holdings Corporation, Allergan, Lantheus, IMol, Medtronic, Nanova Biomaterials Inc., Merck KGaA, Darmstadt, Germany, Hologic, Inc., Biosensors International Group, Ltd, Canon Medical Systems Corporation, Sharp Electronics Corporation USA, Hologic, Inc., W. L. Gore & Associates, Bracco. #MRIContrast #MedicalImaging #ContrastMedia #MRIMarket #MedicalDevices #HealthcareInnovation #ImagingSolutions #ContrastAgents #MRITechnology #DiagnosticImaging #MedicalResearch #ImagingTrends #HealthcareTech #MRIContrastAgents #ImagingAdvancements #ContrastMediaMarket #MedicalImagingTech #MRIUpdates #HealthcareTrends #MedicalImagingMarket

MedTech companies have been actively pursuing the development of minimally invasive procedures that have shorter recovery periods, offer improved patient outcomes and reduced post-procedure discomfort. As the limitations of the existing ablation methods became apparent, Pulsed Field Ablation (PFA) poses a vast growth potential, as it is a safer, more convenient, and more effective alternative. #pfa #pulsedablation #atrialfibrillation #eos

Atrial Fibrillation (AF) is still largely underpenetrated specifically in severe forms of AF that includes persistent, long-standing persistent, and permanent forms. Despite being the smallest segment in the atrial fibrillation market, paroxysmal treatment still represents a multi-billion-dollar addressable market opportunity.   Cardiac arrythmia treatment market represents one of the healthiest segments of the medical device market, growing double digits consecutively in the last few years, yet there is still significant unmet need in the patient community which provides optimism for continued growth in the space. #AtrialFibrillation #CardiacArrhythmia #MedicalDevice #HealthcareIndustry #eosintelligence #perspectives

As the shortage of physicians continues to worsen globally, particularly in the USA, which represented 50% of the ablation market in 2023, PFA can play a crucial role in facilitating an increase in the number of procedures performed at a hospital within the same timeframe. With an expected shortage of 120,000 cardiologists in the USA by 2030, according to a 2021 report by the Association of American Medical Colleges, performing quicker procedures can help to partially offset the lack of specialists. Since PFA takes 30-50% less time than conventional ablation methods, it has the potential to significantly increase the number of procedures performed. #PulsedFieldAblation, #PhysicianShortage, #CardiacHealth, #MedTech, #MinimallyInvasiveMedicine, #AblationTechnology, #EOS Perspective